CHEK
Price
$2.25
Change
+$1.66 (+281.36%)
Updated
Dec 23 closing price
64 days until earnings call
ICAD
Price
$1.69
Change
-$0.15 (-8.20%)
Updated
Dec 23 closing price
64 days until earnings call
Ad is loading...

CHEK vs ICAD

Header iconCHEK vs ICAD Comparison
Open Charts CHEK vs ICADBanner chart's image
Check-Cap
Price$2.25
Change+$1.66 (+281.36%)
Volume$40.09M
CapitalizationN/A
iCAD
Price$1.69
Change-$0.15 (-8.20%)
Volume$240.52K
CapitalizationN/A
CHEK vs ICAD Comparison Chart
Loading...
CHEK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ICAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHEK vs. ICAD commentary
Dec 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHEK is a Hold and ICAD is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Dec 24, 2024
Stock price -- (CHEK: $2.25 vs. ICAD: $1.68)
Brand notoriety: CHEK and ICAD are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CHEK: 4385% vs. ICAD: 82%
Market capitalization -- CHEK: $18.19M vs. ICAD: $42.43M
CHEK [@Medical Specialties] is valued at $18.19M. ICAD’s [@Medical Specialties] market capitalization is $42.43M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHEK’s FA Score shows that 1 FA rating(s) are green whileICAD’s FA Score has 0 green FA rating(s).

  • CHEK’s FA Score: 1 green, 4 red.
  • ICAD’s FA Score: 0 green, 5 red.
According to our system of comparison, ICAD is a better buy in the long-term than CHEK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHEK’s TA Score shows that 5 TA indicator(s) are bullish while ICAD’s TA Score has 4 bullish TA indicator(s).

  • CHEK’s TA Score: 5 bullish, 4 bearish.
  • ICAD’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CHEK is a better buy in the short-term than ICAD.

Price Growth

CHEK (@Medical Specialties) experienced а +265.85% price change this week, while ICAD (@Medical Specialties) price change was -6.91% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -0.30%. For the same industry, the average monthly price growth was +0.69%, and the average quarterly price growth was +2.47%.

Reported Earning Dates

CHEK is expected to report earnings on Feb 26, 2025.

ICAD is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Medical Specialties (-0.30% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ICAD($42.4M) has a higher market cap than CHEK($18.2M). CHEK YTD gains are higher at: 8.173 vs. ICAD (-4.802). ICAD has higher annual earnings (EBITDA): -12.18M vs. CHEK (-18.8M). CHEK has more cash in the bank: 32.1M vs. ICAD (19M). CHEK has less debt than ICAD: CHEK (83K) vs ICAD (514K). ICAD has higher revenues than CHEK: ICAD (25.4M) vs CHEK (0).
CHEKICADCHEK / ICAD
Capitalization18.2M42.4M43%
EBITDA-18.8M-12.18M154%
Gain YTD8.173-4.802-170%
P/E RatioN/AN/A-
Revenue025.4M-
Total Cash32.1M19M169%
Total Debt83K514K16%
FUNDAMENTALS RATINGS
CHEK vs ICAD: Fundamental Ratings
CHEK
ICAD
OUTLOOK RATING
1..100
9918
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
35
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9792
PRICE GROWTH RATING
1..100
9640
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
2850

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CHEK's Valuation (28) in the Medical Specialties industry is in the same range as ICAD (35) in the Computer Peripherals industry. This means that CHEK’s stock grew similarly to ICAD’s over the last 12 months.

CHEK's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ICAD (100) in the Computer Peripherals industry. This means that CHEK’s stock grew similarly to ICAD’s over the last 12 months.

ICAD's SMR Rating (92) in the Computer Peripherals industry is in the same range as CHEK (97) in the Medical Specialties industry. This means that ICAD’s stock grew similarly to CHEK’s over the last 12 months.

ICAD's Price Growth Rating (40) in the Computer Peripherals industry is somewhat better than the same rating for CHEK (96) in the Medical Specialties industry. This means that ICAD’s stock grew somewhat faster than CHEK’s over the last 12 months.

ICAD's P/E Growth Rating (100) in the Computer Peripherals industry is in the same range as CHEK (100) in the Medical Specialties industry. This means that ICAD’s stock grew similarly to CHEK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHEKICAD
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
67%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 5 days ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 7 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 6 days ago
70%
View a ticker or compare two or three
Ad is loading...
CHEK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ICAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PXLW0.700.01
+0.98%
Pixelworks
MFG4.830.01
+0.21%
Mizuho Financial Group
ASPN12.05N/A
N/A
Aspen Aerogels
HCP34.24-0.03
-0.09%
HashiCorp
WLFC204.83-0.22
-0.11%
Willis Lease Finance Corp

CHEK and

Correlation & Price change

A.I.dvisor tells us that CHEK and NVNO have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CHEK and NVNO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHEK
1D Price
Change %
CHEK100%
+281.36%
NVNO - CHEK
27%
Poorly correlated
+16.87%
IINN - CHEK
26%
Poorly correlated
+30.32%
TWST - CHEK
26%
Poorly correlated
+0.38%
RSLS - CHEK
26%
Poorly correlated
-2.74%
ICAD - CHEK
26%
Poorly correlated
-7.92%
More

ICAD and

Correlation & Price change

A.I.dvisor tells us that ICAD and HAE have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ICAD and HAE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ICAD
1D Price
Change %
ICAD100%
-7.92%
HAE - ICAD
32%
Poorly correlated
+2.31%
VMD - ICAD
29%
Poorly correlated
-1.88%
NARI - ICAD
29%
Poorly correlated
-3.99%
HYPR - ICAD
29%
Poorly correlated
-2.46%
CVRX - ICAD
27%
Poorly correlated
+3.22%
More